Analysis of molecular mechanisms and influencing factors of lung cancer after breast cancer treatment

Study on clinicopathological and molecular mechanisms of double primary carcinoma of breast and lung

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040165

Enrollment

Unknown

Registered

2020-11-23

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer and lung cancer

Interventions

Double primary cancer group:No intervention

Single primary lung cancer group:No intervention

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Female breast cancer patients with pathological diagnosis and surgical treatment (modified radical mastectomy, breast-conserving surgery + sentinel lymph node biopsy, simple mastectomy + sentinel lymph node biopsy, etc. Non-palliative surgery) ; 2. aged 18-80 years old; 3. Pulmonary adenocarcinoma was discovered 6 months after breast cancer surgery and received lung tumor resection; 4. Keep enough lung cancer, breast cancer and adjacent specimens for WES testing; 5. Complete clinical pathology and follow-up data; 6. Those who agree to use specimens for gene sequencing.

Exclusion criteria

Exclusion criteria: 1. Combined with other malignant tumors or malignant diseases; 2. Advanced breast cancer.

Design outcomes

Primary

Measure	Time frame
Somatic mutation;mRNA expression;	—

Countries

China

Contacts

Public ContactGuowei Che

West China Hospital, Sichuan University

hxxiongwai@126.com+86 18980601890

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026